Most importantly, intratracheal instillation of shikonin can down-regulate the release of IL-4, IL-5, IL-13, and TNF-α in BALF and reduce pulmonary eosinophils and airway hyperresponsiveness [28]. Here, IL5 is linked to airway hyperresponsiveness.